Work

Quantifying the Benefits of Genome-Driven Oncology

Year: 2017

Type: article

Abstract: Summary: The excitement surrounding genomically selected cancer therapy has led many to question whether this treatment paradigm is living up to its initial promise. The MOSCATO study suggests that a genome-driven strategy for cancer therapy improves outcomes in a significant minority of patients who undergo molecular screening. Cancer Discov; 7(6); 552–4. ©2017 AACR. See related article by Massard et al., p. 586.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-17-0380

Authors: Alison M. Schram, David M. Hyman

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Memorial Sloan-Kettering Cancer Center, National Institutes of Health, National Cancer Institute